S'abonner

Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort - 06/08/11

Doi : 10.1016/S1470-2045(11)70101-2 
Li-Sheng Chen, PhD a, Amy Ming-Fang Yen, PhD a, Sherry Yueh-Hsia Chiu, PhD b, Chao-Sheng Liao, MD c, Hsiu-Hsi Chen, ProfPhD d,
a School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan 
b Department and Graduate Institute of Health Care Management, Chang Gung University, Kwei-Shan, Tao-Yuan, Taiwan 
c Division of Gastroenterology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Shih Lin District, Taipei, Taiwan 
d Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan 

* Correspondence to: Prof Hsiu-Hsi Chen, Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Room 533, 17 Hsuchow Road, Taipei, Taiwan

Summary

Background

Despite widespread use of the immunochemical faecal occult blood test (iFOBT), little is known about the subsequent risk of developing colorectal neoplasia for participants with negative iFOBT results. We investigated whether the concentration of faecal haemoglobin at the first screen is predictive of the subsequent incidence of colorectal neoplasia in those with a negative screening result.

Methods

Between 2001 and 2007, we did a prospective cohort study within the Keelung community-based iFOBT screening programme for residents aged 40–69 years, using a cutoff faecal haemoglobin concentration of 100 ng/mL to classify attendees as negative and positive groups for further clinical investigations. 44324 participants with negative findings and 1668 with a positive result at the first screen (854 non-referrals who refused colonoscopy and 814 with a false-positive result as assessed by colonoscopy) were followed up to ascertain cases of colorectal neoplasia. We investigated the association between baseline faecal haemoglobin concentration and risk of incident colorectal neoplasia, after adjusting for possible confounders.

Findings

Median follow-up was 4·39 years (IQR 2·53–6·12) for all 45992 participants, during which the incidence of colorectal neoplasia increased from 1·74 per 1000 person-years for those with baseline faecal haemoglobin concentration 1–19 ng/mL, to 7·08 per 1000 person-years for those with a baseline concentration of 80–99 ng/mL. The adjusted hazard ratios (HRs) increased from 1·43 (95% CI 1·08–1·88) for baseline faecal haemoglobin concentration of 20–39 ng/mL, to 3·41 (2·02–5·75) for a baseline concentration of 80–99 ng/mL (trend test p<0·0001), relative to 1–19 ng/mL. These results did not change when we included repeated iFOBT measurements. Non-referrals had the highest risk of incident colorectal neoplasia (adjusted HR 8·46 [6·08–11·76]).

Interpretation

Quantitative faecal haemoglobin concentration at first screening predicts subsequent risk of incident colorectal neoplasia. During follow-up, risk stratification based on faecal haemoglobin could help clinicians, with particular attention being paid to those with higher initial faecal haemoglobin concentrations, especially those just under the threshold taken to indicate presence of colorectal neoplasia.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2011  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 12 - N° 6

P. 551-558 - juin 2011 Retour au numéro
Article précédent Article précédent
  • Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis
  • Martijn HGM van der Pas, Sybren Meijer, Otto S Hoekstra, Ingid I Riphagen, Henrica CW de Vet, Dirk L Knol, Nicole CT van Grieken, Wilhelmus JHJ Meijerink
| Article suivant Article suivant
  • Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study
  • Anita Villani, Uri Tabori, Joshua Schiffman, Adam Shlien, Joseph Beyene, Harriet Druker, Ana Novokmet, Jonathan Finlay, David Malkin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.